Why the study?
Is the Arg506Gln Factor V mutation associated with ischaemic cerebrovascular disease or myocardial infarction?
Is the Arg506Gln Factor V mutation associated with ischaemic cerebrovascular disease or myocardial infarction?
The Factor V Leiden mutation does not appear to be a major risk factor for arterial thrombosis such as myocardial infarction or ischaemic stroke, unlike its established role in venous thromboembolism.
Answers are grounded in this paper and cite their sources.
No role for factor V Leiden testing in arterial thrombosis risk assessment; leaves open subtype-specific associations in MI or stroke.
The point mutation Arg506- > Gln of factor V was recently shown to be an important and relatively common genetic cause of venous thromboembolism. Using a DNA technique based on polymerase chain reaction, we surveyed the blood samples of 236 patients with ischaemic stroke or a transient ischaemic attack, 122 survivors of myocardial infarction and 137 control subjects for the presence of this mutation. Although the frequency of the factor V mutation in patients with arterial disease (4.5%) was not significantly different from that in healthy blood donors (2.9%), a carrier status for this mutant gene was associated with symptoms of migraine and relatively mild angiographic abnormalities among patients with cerebrovascular disease. A more extensive study addressing the occurrence and significance of the mutant factor V mutation in patients with vasospastic cerebrovascular diseases seems to be warranted.
No takes yet. Share an insight, caveat, or question.
Kontula et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: